US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.82

-0.0200-1.09%

Post-market: 1.78-0.0400-2.20%19:38 EDT

Volume:186.59K

Turnover:335.11K

Market Cap:51.14M

PE:-2.22

High:1.87

Open:1.79

Low:1.73

Close:1.84

Loading ...

Overview Company News Filings

OS Therapies Receives US Patent Covering Cancer Immunotherapy Platform

MT Newswires Live

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Shares Surge After FDA Agrees to Meeting on Bone Cancer Therapy

Os Therapies FDA Meeting Request Granted

THOMSON REUTERS

Os Therapies Inc - FDA Response Expected by Mid-June 2025

THOMSON REUTERS

Os Therapies Inc - Ost-Her2 Eligible for Priority Review Voucher IF Approved by Sept 2026

THOMSON REUTERS

OS Therapies FDA Meeting Request Granted

OS Therapies announces OST-HER2 data

Os Therapies - Treatment With Ost-Her2 Was Found to Be Safe and Well Tolerated

THOMSON REUTERS

Os Therapies Announces Positive Data for Ost-Her2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

THOMSON REUTERS

Os Therapies -Intends to Conduct Pivotal Clinical Study With Aim of Gaining Full Approval in 2026

THOMSON REUTERS

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals

MT Newswires Live

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

OS Therapies Is Maintained at Buy by D. Boral Capital

BRIEF-OS Therapies Applies For Meeting Per FDA Suggestion Received On April 2, 2025

Os Therapies -Sufficient Cash on Hand to Operate Into Mid-2026

THOMSON REUTERS

Os Therapies Requests Meeting With FDA to Gain Agreement on Surrogate Endpoint(S) for Breakthrough Therapy Designation & Accelerated Approval of Ost-Her2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

THOMSON REUTERS

Os Therapies: Meeting Is Expected to Occur in Q2 of 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OSTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.82,"timestamp":1749844800000,"preClose":1.84,"halted":0,"volume":186589,"hourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"delay":0,"floatShares":18778400,"shares":28097697,"eps":-0.819717,"marketStatus":"Market Closed","change":-0.02,"latestTime":"06-13 16:00:00 EDT","open":1.79,"high":1.87,"low":1.73,"amount":335107.0521604,"amplitude":0.076087,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.819717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.7802,"preClose":1.863,"latestTime":"09:27 EDT","volume":10344,"amount":18630.5763312,"timestamp":1749821265289},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"volumeRatio":0.31820578656515647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":18778400,"roa":"-263.81%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.31820578656515647,"shares":28097697,"dividePrice":0,"high":1.87,"amplitude":0.076087,"preClose":1.84,"low":1.73,"week52Low":1.12,"pbRate":"-12.21","week52High":7,"institutionHeld":0,"latestPrice":1.82,"eps":-0.819717,"divideRate":0,"volume":186589,"delay":0,"ttmEps":-0.819717,"open":1.79,"prevYearClose":4.28,"prevWeekClose":1.67,"prevMonthClose":1.53,"prevQuarterClose":1.54,"fiveDayClose":1.67,"twentyDayClose":1.66,"sixtyDayClose":1.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533025953","title":"OS Therapies Receives US Patent Covering Cancer Immunotherapy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2533025953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533025953?lang=en_us&edition=fundamental","pubTime":"2025-05-07 23:51","pubTimestamp":1746633071,"startTime":"0","endTime":"0","summary":"OS Therapies  said Wednesday it received a US patent protecting its commercial manufacturing process for its listeria monocytogenes-based cancer immunotherapy platform through 2040.The patent covers multiple assets, including lead candidate OST-HER2, which targets pediatric lung metastatic osteosarcoma and is expected to receive US Food and Drug Administration approval by the end of 2025, according to the company.Other programs covered under the patent include OST-AXIL for HPV-related cancers, OST-503 for lung and brain cancers, OST-504 for prostate cancer, and eight pre-clinical immunotherapy candidates.The patent also extends to OST-HER2's potential use in treating osteosarcoma in dogs.OST-HER2 has received Rare Pediatric Disease designation from the FDA and may qualify for a $150 million Priority Review Voucher if granted conditional approval before September 2026, OS Therapies said.Shares of OS Therapies were down nearly 8% in recent trading.Price: 2.16, Change: -0.18, Percent Chan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2532882321","title":"Emmy-Winning Series Debuts Trailer for \"Shelter Me: The Cancer Pioneers\" Offering A Hopeful Look at Breakthrough Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2532882321","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532882321?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:32","pubTimestamp":1746192720,"startTime":"0","endTime":"0","summary":"LOS ANGELES, May 02, 2025----The official trailer for \"Shelter Me: The Cancer Pioneers\" has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15.\"This is one of the most powerful and consequential stories I’ve ever told,\" said Steven Latham, \"Shelter Me\" series Creator and Producer. \"Dogs are helping unlock the future of cancer treatment for people, and the results are incredibly promising.\". The official trailer captures the emotional stakes of the film: dogs that are beloved family members fighting cancer, dedicated and brave people, brilliant scientists and a future where hope comes on four legs. \"Shelter Me: The Cancer Pioneers\" is a powerful reminder of the unbreakable bond between humans and animals and how that relationship may hold the k","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emmy-winning-series-debuts-trailer-133200780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4080","DC","OS","BK4097","BK4017","ADC","OSTX","BK4139"],"gpt_icon":0},{"id":"2529582688","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529582688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529582688?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:19","pubTimestamp":1745331540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2025 10:19 ET (14:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2529095343","title":"OS Therapies Shares Surge After FDA Agrees to Meeting on Bone Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2529095343","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529095343?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:24","pubTimestamp":1745324640,"startTime":"0","endTime":"0","summary":"OS Therapies shares jumped after the company said the Food and Drug Administration has agreed to a meeting to discuss the status of a bone cancer treatment candidate.Shares of OS Therapies rose 19% to $1.78 in premarket trading Tuesday.The company seeks to gain alignment with the regulator on the surrogate endpoint to support breakthrough therapy designation and accelerated approval of OST-HER2 in the prevention of recurrence of Osteosarcoma, or a type of bone cancer, that had spread to the lungs and had been surgically removed.The FDA granted a written response-only meeting, and the development-stage biopharmaceutical company anticipates the regulatory agency's response by mid-June 2025.New York-based OS Therapies plans to make a presentation on its treatment at a conference on June 28.\"We remain on track for an early third quarter submission and are hopeful to receive approval by year-end 2025 in order to bring this life saving treatment to patients in early 2026,\" said Chief Executi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2529370134","title":"Os Therapies FDA Meeting Request Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370134?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:40","pubTimestamp":1745322000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7K3109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2529187370","title":"Os Therapies Inc - FDA Response Expected by Mid-June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529187370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529187370?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:40","pubTimestamp":1745322000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7K3109:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2529137046","title":"Os Therapies Inc - Ost-Her2 Eligible for Priority Review Voucher IF Approved by Sept 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2529137046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529137046?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:40","pubTimestamp":1745322000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7K3109:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2529370021","title":"OS Therapies FDA Meeting Request Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370021","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370021?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:40","pubTimestamp":1745322000,"startTime":"0","endTime":"0","summary":"Written response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. NEW YORK, April 22, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that the US Food & Drug Administration  granted the Company’s meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA granted a written response-only meeting and confirmed that its response would be received by mid-June 2025, in time for the Company to present the statistical analysis as part of the keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT.OST-HER2, an immunotherapy for osteosarcoma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-fda-meeting-request-114000147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","OS","ADC","BK4097","BK4139","OSTX","BK4231","DC","BK4080"],"gpt_icon":0},{"id":"2526356878","title":"OS Therapies announces OST-HER2 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356878?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:52","pubTimestamp":1744285968,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced data in the prevention or delay of amputation during the treatment of primary osteosarcoma for OST-HER2 combined pall...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-announces-ost-her2-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-announces-ost-her2-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OST","OSTX","BK4148","BK4139"],"gpt_icon":0},{"id":"2526974550","title":"Os Therapies - Treatment With Ost-Her2 Was Found to Be Safe and Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2526974550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526974550?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:42","pubTimestamp":1744285324,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO024:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2526550976","title":"Os Therapies Announces Positive Data for Ost-Her2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550976?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:42","pubTimestamp":1744285324,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2526550971","title":"Os Therapies -Intends to Conduct Pivotal Clinical Study With Aim of Gaining Full Approval in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550971?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:42","pubTimestamp":1744285324,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO024:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2526550198","title":"OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550198","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550198?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:42","pubTimestamp":1744285320,"startTime":"0","endTime":"0","summary":"Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of greater than 500 days in 5 out of 15 dogs.Data from new publication in the journal \"Molecular Therapy\" show OST-HER2 induces strong innate and cytotoxic immune responses beginning at the 1st dose of 3 dose regimen, that correlate with prevention of metastasis and long-term survival in dogs with resected primary osteosarcoma.Additionally, the Company announced the publication of positive data in the journal \"Molecular Therapy\" entitled \"Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2\" demonstrated the correlation of innate and adaptive immune responses to OST-HER2, with prevention of metastasis and long-term survival benefit when used in the a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-announces-positive-data-114200323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4080","BK4017","ADC","PFS","BK4195","OSTX","BK4211","DC","BK4139","OST","BK4148"],"gpt_icon":1},{"id":"2526398398","title":"OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2526398398","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526398398?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:18","pubTimestamp":1744208306,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) said Wednesday it closed the acquisition of listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals.The biopharmaceutical company said it h","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2526363883","title":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2526363883","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526363883?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:40","pubTimestamp":1744198800,"startTime":"0","endTime":"0","summary":"Expands clinical pipeline with 3 new cancer immunotherapy candidates. 8 pre-clinical immunotherapy candidates targeting 30+ cancers added. \"The listeria cancer immunotherapy platform holds tremendous potential to improve the outcomes for cancer patients worldwide\" said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. \"Immune-checkpoint inhibitors have revolutionized cancer treatment in settings where tumor antigens have generated a sufficient T cell response. However, in many cancers these treatments don’t help because T cell responses against key tumor antigens have not developed. The OST Listeria platform specifically delivers relevant cancer targets directly to the immune system and generates new T cell responses that can be used to fight these cancers and help eliminate metastases. With OST-HER2 and the rest of the listeria platform, we have the potential to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-completes-acquisition-advaxis-114000244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","LU1169589451.USD","ADC","LU2463526074.USD","IE00B3T34201.USD","LU1481600234.SGD","DC","LU1169590202.USD","OSTX","BK4139","BK4585","BK4231","BK4017","BK4136","LU1481599808.USD","IP","BK4588","LU1487256676.USD"],"gpt_icon":0},{"id":"2525951014","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2525951014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525951014?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:32","pubTimestamp":1744025520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 07:32 ET (11:32 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2525909000","title":"BRIEF-OS Therapies Applies For Meeting Per FDA Suggestion Received On April 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525909000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525909000?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:02","pubTimestamp":1744020125,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies Applies For Meeting Per FDA Suggestion Received On April 2, 2025April 7 (Reuters) - OS Therapies Inc OSTX.A:OS THERAPIES REQUESTS MEETING WITH FDA TO GAIN AGREEMENT ON SURROGATE END","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2525809020","title":"Os Therapies -Sufficient Cash on Hand to Operate Into Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2525809020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525809020?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2525090957","title":"Os Therapies Requests Meeting With FDA to Gain Agreement on Surrogate Endpoint(S) for Breakthrough Therapy Designation & Accelerated Approval of Ost-Her2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090957?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2525090271","title":"Os Therapies: Meeting Is Expected to Occur in Q2 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090271?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":105,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-06-13","current":-4.574874,"percent":0.80543,"low":-14.897496,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"high":-2.731469,"avg":-7.723832,"sd":3.415038,"marketCap":51699762},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762}],"updateTime":1749952039380}}}